The prominence in this network model of HDACs as direct partners for OVOL function, and the NFKB signaling pathway as a regulator of MET-associated genes, offer suggestions that this type of synergistic approach, combining HDAC inhibitors (such as vorinostat) with proteasome inhibitors (such as bortezomib) might have value in advanced prostate and breast cancer. This evidence concerns the gene NFKB1 and breast carcinoma.